| 000 | 01658 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250517070019.0 | ||
| 264 | 0 | _c20160829 | |
| 008 | 201608s 0 0 eng d | ||
| 022 | _a1473-4877 | ||
| 024 | 7 |
_a10.1185/03007995.2015.1130691 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLi, Nanxin | |
| 245 | 0 | 0 |
_aTime on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. _h[electronic resource] |
| 260 |
_bCurrent medical research and opinion _c2016 |
||
| 300 |
_a385-94 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCapecitabine _xadministration & dosage |
| 650 | 0 | 4 |
_aEverolimus _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPostmenopause |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aReceptor, ErbB-2 |
| 650 | 0 | 4 | _aRetrospective Studies |
| 700 | 1 | _aHao, Yanni | |
| 700 | 1 | _aKageleiry, Andrew | |
| 700 | 1 | _aPeeples, Miranda | |
| 700 | 1 | _aFang, Anna | |
| 700 | 1 | _aKoo, Valerie | |
| 700 | 1 | _aWu, Eric Q | |
| 700 | 1 | _aGuérin, Annie | |
| 773 | 0 |
_tCurrent medical research and opinion _gvol. 32 _gno. 2 _gp. 385-94 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1185/03007995.2015.1130691 _zAvailable from publisher's website |
| 999 |
_c25527483 _d25527483 |
||